Vasculitis of the Central Nervous System

1. Comprehensive Introduction & Overview: Primary Angiitis of the Central Nervous System (PACNS)

Primary Angiitis of the Central Nervous System (PACNS), often referred to as primary CNS vasculitis, is a rare, complex, and potentially devastating inflammatory disease restricted to the blood vessels of the brain and spinal cord. Unlike systemic vasculitides, PACNS is characterized by the absence of evidence for any underlying systemic inflammatory or autoimmune process.

The disease typically presents as a subacute or chronic condition characterized by multifocal neurological deficits, cognitive impairment, and, in severe cases, catastrophic stroke or seizure. Because the clinical presentation is highly heterogeneous and mimics numerous other neurological conditions—ranging from infectious encephalitis to neoplasms—it is frequently labeled as a "diagnostic chameleon." Early recognition and aggressive management are critical, as delayed treatment can lead to irreversible neurological damage, permanent disability, or death.

2. Etiology and Pathophysiology: The Mechanisms of Vascular Insult

The exact etiology of PACNS remains idiopathic, though current research points toward a complex interplay between genetic predisposition and environmental triggers.

Pathophysiological Mechanisms

The hallmark of PACNS is the transmural inflammation of the small-to-medium-sized leptomeningeal and parenchymal arteries. This inflammatory process involves several distinct stages:

• Endothelial Activation: Initial triggers (possibly viral or autoimmune) lead to the upregulation of cell adhesion molecules (ICAM-1, VCAM-1) on the vascular endothelium.
• Leukocyte Recruitment: Activated endothelium recruits T-lymphocytes, macrophages, and neutrophils into the vessel wall.
• Vessel Wall Destruction: The infiltration of inflammatory cells causes degradation of the internal elastic lamina. This results in the characteristic "beading" appearance seen on angiography, which represents alternating segments of stenosis (due to inflammation and intimal hyperplasia) and dilation (due to wall weakening/aneurysm formation).
• Ischemic/Hemorrhagic Cascades: The narrowing of the vessel lumen leads to hypoperfusion, resulting in focal ischemia or infarction. Conversely, the weakening of the vessel wall can result in petechial hemorrhages or, rarely, massive intracranial hemorrhage.

Histopathological Classification

PACNS is categorized based on the histological pattern observed in brain biopsies:
| Pattern | Key Feature |
| :--- | :--- |
| Granulomatous | Presence of giant cells, epithelioid macrophages, and T-cell infiltrates. |
| Lymphocytic | Dominated by perivascular lymphocytic cuffs with minimal vessel wall destruction. |
| Necrotizing | Characterized by fibrinoid necrosis and intense inflammation. |

3. Clinical Indications, Presentation, and Staging

The clinical manifestations of PACNS are highly variable, depending on the size and location of the affected vessels.

Standard Clinical Presentation

• Cognitive Dysfunction: Often presents as a progressive decline in memory, executive function, or personality changes (seen in ~50-70% of patients).
• Headaches: Frequently chronic, severe, and refractory to standard analgesics.
• Focal Neurological Deficits: Hemiparesis, aphasia, visual field cuts, or cranial nerve palsies.
• Seizures: Can be a presenting symptom, often focal with secondary generalization.
• Encephalopathy: Acute confusion or altered mental status, sometimes mimicking delirium or psychiatric disorders.

Clinical Staging/Grading

While there is no universally adopted "staging" system like cancer, clinicians often utilize the Calabrese and Mallek criteria for diagnosis, which acts as a proxy for clinical assessment:
1. Acquired neurological deficit(s) (e.g., stroke, cognitive impairment).
2. Angiographic or histopathological evidence of vasculitis.
3. Absence of evidence of a systemic vasculitic process or other condition that could explain the symptoms.

4. Differential Diagnosis: Ruling Out the Mimics

The primary challenge in PACNS is its overlap with other pathologies. A rigorous diagnostic workup must exclude:

• Infections: Neurosyphilis, Lyme disease, tuberculous meningitis, fungal infections, and viral encephalitis (e.g., VZV vasculopathy).
• Systemic Vasculitis: SLE, Polyarteritis Nodosa (PAN), Sjögren’s syndrome, and Behçet’s disease.
• Reversible Cerebral Vasoconstriction Syndrome (RCVS): The most common mimic. RCVS usually presents with "thunderclap" headache and shows reversible vasoconstriction within 3 months, whereas PACNS is progressive and inflammatory.
• Neoplasms: Primary CNS lymphoma or intravascular lymphoma.
• Drug-induced Vasculitis: Cocaine or amphetamine-induced angiopathy.

5. Key Diagnostic Tests and Clinical Workflow

Diagnosis requires a multimodal approach. No single test is 100% sensitive or specific.

Diagnostic Hierarchy

1. MRI/MRA: The frontline imaging tool. Look for multifocal ischemic lesions (DWI/ADC), leptomeningeal enhancement (gadolinium), and vessel wall abnormalities on high-resolution vessel wall imaging (VWI).
2. Lumbar Puncture (CSF Analysis): Often shows elevated protein, pleocytosis (usually lymphocytic), and rarely, oligoclonal bands. It is essential for ruling out infections.
3. Digital Subtraction Angiography (DSA): The "gold standard" for large/medium vessel PACNS. Findings include multiple areas of stenosis and dilation ("beading"). Note: DSA is normal in 20-40% of small-vessel PACNS cases.
4. Brain Biopsy: The definitive diagnostic test. A leptomeningeal and parenchymal biopsy is recommended to confirm the vasculitic nature and exclude other etiologies.

6. Management, Risks, and Prognosis

Treatment Protocols

Treatment is divided into two phases:
* Induction Therapy: Typically involves high-dose intravenous corticosteroids (e.g., methylprednisolone 1g/day for 3–5 days) followed by oral prednisone and often cyclophosphamide for aggressive disease.
* Maintenance Therapy: Transitioning to safer immunosuppressants such as Azathioprine, Mycophenolate Mofetil, or Rituximab once remission is achieved.

Risks and Side Effects

Aggressive immunosuppression carries significant risks:
* Infection: Opportunistic infections are a major cause of morbidity.
* Marrow Suppression: Specifically associated with cyclophosphamide.
* Steroid Toxicity: Osteoporosis, avascular necrosis, hyperglycemia, and psychiatric disturbances.

Long-Term Prognosis

Prognosis has improved significantly with modern immunosuppressive regimens. However, patients often experience:
* Relapse: Occurs in approximately 25% of patients.
* Long-term Deficits: Many patients are left with chronic cognitive impairment or residual focal deficits.
* Mortality: Much lower than the pre-steroid era, but still requires vigilant monitoring for long-term complications.

7. Massive FAQ Section

1. Is PACNS a form of stroke?
PACNS is not a stroke itself, but it is a major cause of stroke. It causes inflammation that restricts blood flow, leading to ischemic or hemorrhagic strokes.

2. How common is Primary CNS Vasculitis?
It is extremely rare, with an estimated incidence of approximately 2.4 cases per 1,000,000 person-years.

3. Why is a brain biopsy necessary if I have an angiogram?
An angiogram (DSA) is only sensitive to medium-sized vessels. If the vasculitis is limited to small vessels (small-vessel PACNS), the angiogram will appear normal, making a biopsy the only way to confirm the diagnosis.

4. Can PACNS be cured?
It can be brought into long-term remission, but "cure" is a difficult term. Patients often require maintenance medication for years and must be monitored for potential relapses.

5. What is the difference between PACNS and RCVS?
RCVS is non-inflammatory and typically resolves on its own within weeks. PACNS is inflammatory and usually progressive, requiring aggressive immunosuppressive therapy.

6. Does PACNS affect the rest of the body?
By definition, PACNS is restricted to the CNS. If a patient has systemic symptoms (rash, joint pain, kidney issues), the diagnosis is likely a systemic vasculitis manifesting in the CNS, not primary CNS vasculitis.

7. Is there a genetic test for PACNS?
No. There is no known single genetic marker for PACNS. It is considered a complex, multifactorial condition.

8. What is the most common symptom?
Headache is the most common symptom, though it is non-specific. Cognitive changes are the most common neurological deficit observed.

9. Are steroids the only treatment?
Steroids are the foundation of treatment, but they are rarely enough on their own. Cyclophosphamide is usually required for induction, especially in patients with severe, biopsy-proven disease.

10. How long does the recovery process take?
Recovery is slow. While inflammation may be controlled within weeks, neurological recovery (if possible) may take months of rehabilitation and physical therapy.

8. Summary Table for Clinical Reference

Disclaimer: This guide is for educational purposes for healthcare professionals and clinical students. It does not constitute medical advice. Always consult current clinical guidelines and neurology consultation services when managing suspected cases of central nervous system vasculitis.